D
Dewpoint Therapeutics
First company to apply the emerging understanding of biomolecular condensates to drug discovery
About Dewpoint Therapeutics
Dewpoint Therapeutics is a pioneering biotechnology startup that operates in the field of biomolecular condensates. The company's primary focus is on understanding and treating complex diseases by exploring the dysregulation of these condensates. In simpler terms, biomolecular condensates are tiny droplets inside cells that play a crucial role in cell function and organization. Dewpoint believes that when these condensates don't work properly, it can lead to complex diseases.
The company has assembled a team of experts in condensate science, drug discovery, and data science, making it a global leader in condensate biotechnology. Dewpoint integrates artificial intelligence (AI) with cutting-edge experimental technologies to discover new therapeutic possibilities.
Dewpoint's business model revolves around developing and commercializing novel therapies. They have a robust pipeline of discovery programs and have established collaborations with leading global pharmaceutical partners. One of their recent collaborations aims to explore the use of biomolecular condensates in treating insulin resistance and diabetes progression.
The company generates revenue through the development and commercialization of these novel therapies, as well as through strategic partnerships with other pharmaceutical companies. Dewpoint's innovative approach and promising pipeline position it well for future growth and success in the biotechnology industry.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- Boston, United States
- Employees
- 58
- Open positions
- 1
- Dealroom signal
- 62.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Molecular Biology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES DOther financing | Sep 2025 | — | — | Undisclosed | ↗ |
| SERIES COther financing | Feb 2022 | $150M | $600M | Polaris Partners · SoftBank · Maverick Ventures · Timefolio Capital | ↗ |
Growth signals
Latest recorded traffic for Dewpoint Therapeutics is 7.1K monthly website visits, up 34% over the last three months. Dewpoint Therapeutics's team declined 9.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A10 investors entered at this stage
Polaris Partners
Alexandria Venture Investments
6 Dimensions Capital
EcoR1 Capital
Samsara BioCapital
Leaps by Bayer
ARCH Venture Partners
Innovation Endeavors
Maverick Ventures
Bellco Capital
Series B and later6 investors entered at this stage
SoftBank Vision Fund
SoftBank- TCTimefolio Capital
3E Bioventures
General Catalyst
Mubadala Capital
Other known investors2 additional known investors
Max Planck Innovation
Max Planck Society
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Dewpoint Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Dewpoint Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.